Archive for the ‘Parkinson's Disease’ Category
Monday, March 3rd, 2008
International Stem Cell Corporation (OTCBB:ISCO) announced that its human parthenogenetic stem cell lines will be used in Germany in studies aimed at creating specific cell types to treat human neural diseases such as Parkinson's disease.
The work will be headed by Dr. Albrecht Mueller of the University of Wuerzburg, Wuerzburg, Germany ...
Posted in Parkinson's Disease | No Comments »
Monday, December 3rd, 2007
Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) announced that it has entered an exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd) with the goal of developing a new class of orally available drugs, initially as ...
Posted in Parkinson's Disease | No Comments »
Thursday, November 1st, 2007
Researchers at the Saint Louis University School of Medicine have discovered the key brain chemical that causes Parkinson's disease -- a breakthrough finding that could pave the way for new, far more effective therapies to treat one of the most common and debilitating neurological disorders.
Currently, the main approach for treating ...
Posted in Parkinson's Disease | No Comments »
Thursday, November 1st, 2007
Barr Pharmaceuticals, Inc. (NYSE: BRL) announced that its subsidiary, Barr Laboratories, Inc., has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex(R) (Pramipexole Dihydrochloride) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg. The Company believes that it is the ...
Posted in Parkinson's Disease | No Comments »
Tuesday, October 9th, 2007
UCB, Inc. presented data from two clinical trials that showed Neupro® (Rotigotine Transdermal System), a once-daily non-ergolinic dopamine agonist patch, is effective in controlling early morning motor impairment, provides improvement in sleep quality, and is generally well-tolerated for long-term use in patients with Parkinson's disease. Studies examining patients who have ...
Posted in Parkinson's Disease | No Comments »
Sunday, September 2nd, 2007
Preliminary results of the pan-European PRODEST study in 1016 patients with Parkinson`s disease (PD) were presented at the 11th Congress of the European Federation of Neurological Societies (EFNS) in Brussels this week, revealing unique features of PD-related depression and its treatment.1 The study confirmed that depressive symptoms associated with PD ...
Posted in Parkinson's Disease | No Comments »
Thursday, August 9th, 2007
Novartis Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new higher dose strength of Stalevo(R) (carbidopa, levodopa and entacapone) which is indicated for Parkinson's disease patients with signs and symptoms of end-of-dose "wearing off." The approval of the Stalevo 200 mg dose (50 mg ...
Posted in Parkinson's Disease | No Comments »
Tuesday, August 7th, 2007
A new US study suggests that preschool children prefer the taste of fast food and drinks from McDonald's branded packages to the same food and drinks from unbranded packages.
The study is reported in the August issue of the Archives of Pediatrics & Adolescent Medicine, one of the journals in the ...
Posted in Parkinson's Disease, Rehabilitation, press releases | No Comments »
Monday, July 9th, 2007
In the vast majority of Parkinson's disease (PD) patients, the disorder arises not because of a genetic defect, but because some external insult triggers the death of dopamine-producing neurons. Now, researchers have reported progress in understanding the mechanism underlying that death, which they say suggests a new treatment pathway.
In both ...
Posted in Biology / Biochemistry, Neurology / Neuroscience, Parkinson's Disease | No Comments »
